A leader in the development of innovative interactive on-line.

‘We are thrilled to partner with CCO to provide their unique educational programming and their fresh, innovative point-of-care program to our membership to further support our mission of improving patient treatment.’ Related StoriesAMSBIO launches Mimetix 3D cell tradition scaffolds for drug discovery, oncology researchFDA approves LONSURF for treatment of individuals with metastatic colorectal cancerMirati to provide data on tyrosine kinase inhibitor at ESMO 2015 European Malignancy CongressUS Oncology is rolling out a fresh and innovative platform known as The Oncology Portal, which provides a centralized area for oncology clinicians to access community discussions, practice-based forms and information, and clinical info.In preclinical research, AVEO’s proprietary anti-RON antibodies have got demonstrated strong anti-tumor activity. AVEO is usually primarily receiving $15 million. Under the terms of the license contract, AVEO will have the first half of the amount as an up-front side payment from Centocor Ortho Biotech. Through another equity private positioning and stock purchase agreement, the second fifty % will end up being received through the sale of recently issued shares of AVEO common stock to an affiliate marketer of Centocor Ortho Biotech, Johnson & Johnson Development Company.